RXRX EPS beats
RXRX posted a small EPS beat, kept expense guidance intact, and highlighted a Sanofi milestone plus early clinical responses.
Sources: https://www.financhill.com/stocks/nasdaq/rxrx/earnings
Previous verdicts for RXRX
- AI Search: Sanofi Options First Program as RXRX Rallies Sharply — 2026-11-04
- AI Search: Recursion Q3 Beat Meets a Modest Sell-Off as Investors Take Profits — 2026-11-03
- AI Search: Industry Report Spotlight Lifts Recursion Pharmaceuticals Modestly Higher — 2026-10-28
- AI Search: Needham Buy Reiteration and Cathie Wood Buying Lift Recursion — 2026-10-19
- Dilutive Share Sale — 2026-10-16
Ezbrisk weighs each event against the market reaction and publishes a verdict with an overreaction reading. How the methodology works